AVDL vs. COLL, BCYC, BDSI, IMUX, AGLE, BBIO, OGN, IONS, CYTK, and APLS
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Collegium Pharmaceutical (COLL), Bicycle Therapeutics (BCYC), BioDelivery Sciences International (BDSI), Immunic (IMUX), Aeglea BioTherapeutics (AGLE), BridgeBio Pharma (BBIO), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), and Apellis Pharmaceuticals (APLS). These companies are all part of the "medical" sector.
Avadel Pharmaceuticals (NASDAQ:AVDL) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability.
69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 4.0% of Avadel Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Collegium Pharmaceutical received 46 more outperform votes than Avadel Pharmaceuticals when rated by MarketBeat users. However, 65.22% of users gave Avadel Pharmaceuticals an outperform vote while only 65.16% of users gave Collegium Pharmaceutical an outperform vote.
Collegium Pharmaceutical has a net margin of 16.46% compared to Avadel Pharmaceuticals' net margin of -284.42%. Collegium Pharmaceutical's return on equity of 104.98% beat Avadel Pharmaceuticals' return on equity.
Avadel Pharmaceuticals has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.
In the previous week, Collegium Pharmaceutical had 7 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 4 mentions for Avadel Pharmaceuticals. Avadel Pharmaceuticals' average media sentiment score of 0.70 beat Collegium Pharmaceutical's score of 0.60 indicating that Avadel Pharmaceuticals is being referred to more favorably in the media.
Avadel Pharmaceuticals presently has a consensus price target of $24.17, suggesting a potential upside of 51.52%. Collegium Pharmaceutical has a consensus price target of $39.00, suggesting a potential upside of 17.68%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Avadel Pharmaceuticals is more favorable than Collegium Pharmaceutical.
Collegium Pharmaceutical has higher revenue and earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
Avadel Pharmaceuticals and Collegium Pharmaceutical tied by winning 9 of the 18 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
